Imatinib mesylate(甲磺酸伊马替尼) is a tyrosine kinase inhibitor with antineoplastic activity.

Afatinib Dimaleate(阿法替尼双马来酸盐) is the dimaleate salt form of afatinib, an orally bioavailable anilino-quinazoline derivative and inhibitor of the receptor tyrosine kinase (RTK) epidermal growth factor receptor (ErbB; EGFR) family, with antineoplastic activity.

Sunitinib Malate(苹果酸舒尼替尼) is a multi-targeted RTK inhibitor. Sunitinib blocks the tyrosine kinase activities of VEGFR2, PDGFRb, and c-kit, thereby inhibiting angiogenesis and cell proliferation. This agent also inhibits the phosphorylation of FLT3.

Osimertinib Mesylate(迈瑞替尼甲磺酸盐) is a Kinase Inhibitor. The mechanism of action of osimertinib is as a Kinase Inhibitor, and Cytochrome P450 3A Inhibitor, and Cytochrome P450 3A4 Inducer, and Cytochrome P450 1A2 Inducer, and Breast Cancer Resistance Protein Inhibitor.

Imatinib(伊马替尼) is an antineoplastic agent that inhibits the Bcr-Abl fusion protein tyrosine kinase.

Cabozantinib(卡博替尼) is an orally bioavailable, small molecule receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity.

Sunitinib(舒尼替尼) is an indolinone derivative and tyrosine kinase inhibitor with potential antineoplastic activity.

Afatinib(阿法替尼) is an orally bioavailable inhibitor of the receptor tyrosine kinase (RTK) epidermal growth factor receptor (ErbB; EGFR) family, with antineoplastic activity.